EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zu Erstlinien-Chemotherapie und Trastuzumab mit oder ohne Bevacizumab bei Patient:innen mit HER2/neu-positivem metastasiertem Mammakarzinom: eine Studie der ECOG-ACRIN Cancer Research Group (E1105)

Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, Carlos L Arteaga, Ximing J Yang, Lynne I Wagner, David Cella, Neal J Meropol, R Katherine Alpaugh, Thomas J Saphner, Robert E Swaney, Karen L Hoelzer und 10 weitere

Breast Cancer Research and Treatment · 2024-09 · 207 (2) · 275-282

DOI: 10.1007/s10549-024-07417-4 ↗

Auf einen Blick

Bei 93 behandelten Patient:innen mit HER2-positivem metastasiertem Mammakarzinom verlängerte Bevacizumab die mediane PFS nicht signifikant. Auch das Gesamtüberleben unterschied sich nicht signifikant.

Fragestellung

Verbessert Bevacizumab zusätzlich zu Erstlinien-Chemotherapie und Trastuzumab das progressionsfreie Überleben bei HER2-positivem metastasiertem Mammakarzinom?

Methode

Randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie; 96 randomisiert, 93 begannen die Protokolltherapie; Induktion 24 Wochen, danach Erhaltung mit Trastuzumab mit oder ohne Bevacizumab.

Ergebnisse

Medianes PFS: 11,1 Monate unter Placebo und 13,8 Monate unter Bevacizumab; HR 0,73 (95 %-KI 0,43–1,23), p = 0,24. Medianes Überleben: 49,1 vs. 63 Monate; HR 1,09 (95 %-KI 0,61–1,97), p = 0,75. Häufig: Neutropenie, Hypertonie.

Einschränkungen

Unterpowert wegen kleinerer als erwarteter Stichprobe.

Schlussfolgerung der Autor:innen

Die Zugabe von Bevacizumab verbesserte die Outcomes bei Patient:innen mit metastasiertem HER2-positivem Mammakarzinom nicht.

Kernaussagen

  • PFS: 11,1 vs. 13,8 Monate
  • HR 0,73 (95 %-KI 0,43–1,23); p = 0,24
  • Unter Bevacizumab häufiger linksventrikuläre Dysfunktion, Fatigue und sensorische Neuropathie

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 05.07.2024. Verfasst von Jessica Mezzanotte-Sharpe und 21 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN, 37232-6307, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Bevacizumab, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, CCR NIH HHS, National Cancer Institute.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the pre-clinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC.

Findings

96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy. Induction therapy was given for 24 weeks, followed by maintenance trastuzumab with or without bevacizumab. 60% (56/93) began carboplatin and 74% (69/93) completed 6 cycles of induction therapy. Primary endpoint was PFS. Median PFS was 11.1 and 13.8 months for placebo and bevacizumab arms, respectively (hazard ratio [HR] 95%, Confidence Interval [Cl] for bevacizumab vs. placebo: 0.73 [0.43–1.23], p = 0.24), and at a median follow-up of 70.7 months, median survival was 49.1 and 63 months (HR [95% Cl] for OS: 1.09 [0.61–1.97], p = 0.75). The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab.

Conclusions

In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer. Although the trial was underpowered due to smaller than anticipated sample size, these findings corroborated other clinical trials during this time. Clinical Trial Information: NCT00520975

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBevacizumabErb-b2 Receptor Tyrosine KinasesTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultAgedNeoplasm MetastasisDouble-Blind MethodTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

BevacizumabBreast cancerChemotherapyTrastuzumab

Substanzen

BevacizumabErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN, 37232-6307, USA.
  • Dana-Farber Cancer Institute, Boston, MA, USA.
  • UT Southwestern/Simmons Cancer Center, Dallas, TX, USA.
  • Northwestern University, Chicago, IL, USA.
  • Wake Forest University Health Sciences, Winston Salem, NC, USA.
  • Case Western Reserve University, Cleveland, OH, USA.

Förderung

  • NCI NIH HHS
  • CCR NIH HHS
  • National Cancer Institute
  • Center for Cancer Research

Zitieren

APA

Mezzanotte-Sharpe, J., ONeill, A., Mayer, I. A., Arteaga, C. L., Yang, X. J., Wagner, L. I., Cella, D., Meropol, N. J., Alpaugh, R. K., Saphner, T. J., Swaney, R. E., Hoelzer, K. L., Gradishar, W. J., Abramson, V. G., Sundaram, P. K., Jilani, S. Z., Perez, E. A., Lin, N. U., Jahanzeb, M., …, & Reid, S. A. (2024). A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105). Breast Cancer Research and Treatment, 207(2), 275-282. https://doi.org/10.1007/s10549-024-07417-4

Vancouver

Mezzanotte-Sharpe J, ONeill A, Mayer IA, Arteaga CL, Yang XJ, Wagner LI, et al. A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105). Breast Cancer Research and Treatment. 2024;207(2):275-282. doi:10.1007/s10549-024-07417-4

BibTeX
@article{MezzanotteSharpe2024,
  author = {Mezzanotte-Sharpe, Jessica and ONeill, Anne and Mayer, Ingrid A and Arteaga, Carlos L and Yang, Ximing J and Wagner, Lynne I and Cella, David and Meropol, Neal J and Alpaugh, R Katherine and Saphner, Thomas J and Swaney, Robert E and Hoelzer, Karen L and Gradishar, William J and Abramson, Vandana G and Sundaram, P Kothai and Jilani, Shamim Z and Perez, Edith A and Lin, Nancy U and Jahanzeb, Mohammad and Wolff, Antonio C and Sledge, George W and Reid, Sonya A},
  title = {A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  volume = {207},
  number = {2},
  pages = {275--282},
  doi = {10.1007/s10549-024-07417-4}
}
Kostenlos starten →